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ABSTRACT 
 
Objectives: There are three aims for this thesis: the first is to develop a field and 
laboratory protocol for the storage and analysis of transforming growth factor–beta 2 
(TGF-β2) in human breastmilk; second, to validate this protocol and the immunoassay 
used to assess this new method; and lastly, to explore the ramifications of biosimilar 
TGF-β2 across multiple milks on human health, growth, and immunity through the 
review of laboratory findings and previous literature.  
Rational: Little anthropological research has been done on TGF-β2 in human 
milk. Anthropology as a discipline is well positioned to provide insight into TGF-β2, 
combining biocultural, evolutionary, and ecological approaches to holistically illustrate 
the effects this cytokine has on human immunity. This thesis provides an applied 
anthropological perspective and methodology on TGF-β2 in human milk.  
Methods: A protocol was developed for a new method of drying breastmilk on 
polystyrene microplates. Samples were then reconstituted using reagent diluent with 
1% BSA and assayed using a Human TGF-beta 2 DuoSet enzyme-linked 
immunosorbent assay (ELIZA) assay kit from R&D Systems. Other mammalian milks 
and infant formula samples were also dried and tested for TGF-β2 concentrations. 
vi 
 
Validity of the assay and TGF-β2 concentrations were then statistically measured using 
linear regression analysis and Bland-Altman plots.  
Results: The results of the first objective in the development of a laboratory and 
field protocol for drying breastmilk on polystyrene plates for the extraction of TGF-β2 
showed this method to hold promise for future application, but lacked statistical power 
in this study to confirm if this method is viable. The second objective of assay validation 
was unsuccessful, with the percent coefficient of variation for the intra-assay variation 
and inter-assay validation 38.28% and 17.70%, respectively indicating that this assay 
struggled to produce consistent and reliable results from the reconstituted samples. 
Results from the third objective suggest that biosimilar TGF-β2 in non-human milk can 
influence human growth and development, the extent of which, however, needs further 
study. 
Conclusions: Given these findings, more work with TGF-β2 in milk is required. 
TGF-β2 is a cytokine which could reveal a great deal about the developmental origins of 
human immunity and how it is maintained and altered across our life course and 
therefore an area of biology worth further research.  
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CHAPTER ONE: 
INTRODUCTION 
 
 Fueled by a scientific curiosity to learn more about the development of human 
growth and health, the last decade of human biological research has shown increasing 
interest in human milk and breastfeeding. Studies have explored multiple facets of 
human milk, including immunity, growth, development, the microbiome, reproduction, 
evolution, as well as long and short term effects on health and illness (Ballard and 
Morrow 2013; Böttcher et al. 2008; Donnet-Hughes et al. 2000; Miller et al. 2013; Miller 
and McConnell 2015; Miller and McConnell 2011). As more is revealed about the 
importance of human milk, however, human biologists often find themselves with more 
questions about the confluence of these facets and the outcome it may have on health. 
 Breastmilk and the role it plays in immune development, function, and 
maintenance is one such area of intersectional research. Early environmental exposures 
have been found to establish the developmental parameters of immunity for the 
duration of the life course through the interaction of various ecological components 
(Georgiev et al. 2016; McDade et al. 2012; Sadd and Schmid-Hempel 2009). The outcome 
of the interconnections of multiple environmental and evolutionary variables create 
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unique ecological immunities (McDade 2012; Sadd and Schmid-Hempel 2009). Among 
these environmental factors, breastmilk figures prominently, providing critical 
biological building blocks for infant immune development (Miller 2018).  
 Research has shown that there are several bioactive immune modulators in 
breastmilk which contribute to infant immune development, passive immunity as well 
as through fostering a foundation for the infant’s singular immune system to mature 
independent of the maternal environment (Baumgartel et al. 2016; Kuzawa et al. 2012; 
Miller 2018; Miller and McConnell 2015; Miller and McDade 2012; Oddy and McHahon 
2011). Of these immune modulators, recent evidence has highlighted the potential 
importance of the anti-inflammatory cytokine transforming growth factor–beta 2 (TGF-
β2) in breastmilk as critical not only to the development of the human immune system, 
but also to overall growth and long-term health (Baumgartel et al. 2016; Donnet-Hughes 
et al. 2000; Gordon and Blobe 2007; Miller 2018; Mir et al. 2015; Namachivayam et al. 
2015; Oddy and McHahon 2011; Oddy and Rosales 2010; Ogawa et al. 2004; Penttilä et 
al. 2003; Verhasselt 2010). However, a limited amount of research has been done on 
TGF-β2 in breastmilk or its effects on health and growth once is has been consumed.  
 This thesis intends to expand the scope of understanding of the function of TGF-
β2 in human breastmilk and the role it plays in the foundational creation of individual 
health and immunity, the effects of which may stretch across the life course. The 
overarching objective is to create the groundwork for the further study of TGF-β2 
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within human biology, compiling previous and new findings about this cytokine. To do 
so, this thesis will utilize an evolutionary perspective to explore the biological and 
ecological function of TGF-β2 in breastmilk and its effects on growth and immunity.  
 A biocultural framework will also be used to explore the material and findings. 
Our biology and health are shaped and influence not only by our physical 
environments, but also by the cultural structures in which we live (Wiley and Cullin 
2016). Therefore, when researching the impact of human milk on our biology, one must 
not only consider the biological ramifications upon the life course, but also the effects of 
the cultural ones. What sort of feeding habits do mothers employ? How is milk utilized 
within a culture? Are infants given human milk at all or is it substituted for other foods?  
 For this reason, it is imperative that a biocultural perspective is maintained in 
human milk research, understanding that – in this juncture of the cultural and the 
biological – human milk may not be part of the research question at all. Many 
populations and cultural sub-sets do not partake in the recommended six months of 
exclusive breastfeeding (WHO 2017), relying instead on the use of formula, early 
introduction of solid foods, and / or the incorporation of non-human mammalian milks 
to feed their infants (Martin 2018; Thompson 2013; Thompson et al. 2009; Wiley 2007). 
Therefore, in order to adequately research the effects of the many biocultural facets of 
human milk, the future of this field may perhaps require a shift to instead investigate the 
human consumption of milks.  
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 Humans have an extensive history with drinking the milk of other animals, a 
relationship which evolved to be biologically sustained from its positive benefits on 
early human nutrition and, by proxy, growth and health (Ségurel and Bon 2017; Wiley 
2014). Bovine milk consumption during early life stages has been found to have a 
growth-promoting effect on humans due to a high intestinal absorption rate, most 
notably improving children’s height outcomes as they enter adulthood (Purup et al. 
2006; Wiley 2009, 2007, 2005). Evidence has also been found that TGF-β2 in bovine milk 
is linked with immune development and regulation of that humans who consume it 
(Donnet-Hughes et al. 2000; Rogers et al. 1996).  
While this thesis primarily revolves around an examination of TGF-β2 in human 
milk, new laboratory findings involving TGF-β2 in bovine milk and bovine milk-based 
infant formula will also be discussed. Therefore, the purpose of this study is to employ 
evolutionary and biocultural perspectives to quantify TGF-β2 in human breastmilk, 
bovine milk, and infant formula and the potential effects on human immunity and 
health. To achieve this, an extensive review of the literature will be conducted in 
tandem with laboratory work.  
There are three primary aims for this thesis. The first aim is to develop an 
original laboratory protocol for the field preservation and laboratory analysis of the 
cytokine TGF-β2 in human breastmilk. As previously stated, the general goal of this 
study is to lay the foundations for future research of TGF-β2 in human biology, 
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specifically in regards to breastmilk. Outside of refrigeration and freezing, no method to 
my knowledge has been developed for the field acquisition and storage of breastmilk 
with the expressed purpose of the extraction of TGF-β2 in the laboratory (Miller et al. 
2013). In this regard, this thesis is pioneering new territory of field methodologies for 
cytokine preservation in human breastmilk. It is my hope that this new method for 
sample collection and analysis will lead not only to an increase in human milk research, 
but will also have the capacity to be applied within multiple geographic settings, and – 
potentially – to the analysis of additional biomarkers.  
 The second aim for this study is to validate the efficacy of this new protocol in 
addition to the assay which was used to analyze the samples. Several tests were 
conducted to assess the precision, accuracy, and reliability of the TGF-β2 assay for 
sample analysis, in addition to multiple stability tests to measure the results of the new 
protocol. This second aim is critical to confirm and demonstrate that the new protocol is 
a reliable instrument for dried breastmilk sample analysis and is able to consistently be 
reproduced by others.  
 The final aim of this thesis is to assess the new finding of biosimilarities in TGF-
β2 in human breastmilk, mammalian livestock milk, and human baby formula. This 
relationship will be explored through the combination of literature review and the 
presentation of laboratory findings. Together, all three of these aims seek to present a 
holistic, biocultural illustration of TGF-β2 in milk as well as pave the way for further 
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research in this field. These new findings of biosimilar TGF-β2 across mammalian milks 
highlight the need to approach human milk research from a multi-milk perspective, 
specifically so we might better understand the role this cytokine plays in potential 
health outcomes for infant growth and development through evolutionary life history 
and sociocultural lenses.   
 The expected outcome for the first aim of this thesis is the development of a 
functional protocol and methodology for the field storage and preservation of 
breastmilk samples for the extraction and laboratory analysis of TGF-β2. The intention 
for this aim is that this protocol can then be utilized for further research within the 
Health and Human Biology Laboratory and beyond for future TGF-β2 research. This, 
however, can only come to fruition with a successful validation of this protocol within 
the assay used. The expected outcome from the third aim is the furthered 
understanding of the role and importance of TGF-β2 in milk in human growth and 
immunological maintenance, specifically in regards to chronic inflammation and 
disease.   
 This thesis has been organized into chapters which reflect the organization of a 
traditional scientific paper. Chapter Two provides a robust insight into previous work 
on TGF-β2, reviewing research and discoveries about the cytokine in health and 
evolution. Chapter Three details the methods used for this thesis and development of 
the original protocol for aim one. It will also review the laboratory methods and 
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procedures used. Chapter Four discusses the results of the laboratory work as well as 
the statistical findings of the study. Chapter Five analyses the significance of these 
results in a biocultural context and explores the implications the findings have within 
an evolutionary health framework. Finally, Chapter Six examines the ethical 
considerations of the study as well as future applications for the work both within and 
beyond academia.  
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CHAPTER TWO: 
SUPPORTING LITERATURE 
 
 This chapter reviews contemporary literature and research on the evolution TGF-
β2 and its role in immunity. Here, I discuss the influence of energetic trade-offs, 
localized biological ecologies and cultural environments on the biological variability of 
TGF-β2 and human immunity. This discussion is extended to encompass the 
evolutionary advantages of breastfeeding and how breastmilk plays an important role 
in the intergenerational exchange of immunity and immune development via cytokines, 
specifically TGF-β2. Recognizing that humans often employ various feeding practices 
and lactational strategies to feed their infants, a multi-milk perspective is needed to 
understand the biological effects of TGF-β2 of infant growth and development when 
obtained from sources other than human breastmilk. Given the importance of TGF-β2 in 
the formative stages of human immune development, this biocultural entanglement of 
variables calls for anthropological research to explore the potential effects they may 
have on long-term health outcomes, specifically chronic and autoimmune diseases.  
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Transforming growth factor beta–2: Evolving Immunity   
  TGF-β2 is a cytokine, a protein which is secreted for the purpose of cell signaling 
and cellular communication (Agarwal et al. 2011; Heldin et al. 2009; Penttilä 2010; 
UniProt P61812 2017). The cytokine TGF-β2 is the product of the gene TGFβ2 which 
codes for the secretion of the super family of TGF-beta proteins (NCBI 7042 2018; 
Heldin et al. 2009; UniProt P61812 2017; Wu and Hill 2009). Due to their signaling 
function, TGF-beta cytokines are found in a variety of cells, from epithelial to immune 
cells (NCBI 7042 2018; UniProt P61812 2017).  
 As a cell signaler, the cytokine TGF-β2 is crucial for the function and 
maintenance of multicellular life. Because of this, the gene TGFβ2, and therefore the 
cytokine TGF-β2, can be found in all metazoa, with orthologs found in macaques, 
pigeons, frogs, zebrafish, beluga whales, koalas, crocodiles, pangolins, and even 
bearded dragons to name a few (NCBI 7042 2018; Penttilä 2010; Wu and Hill 2009). This 
extensive genetic conservation of TGFβ2 indicates that it has been evolutionary 
conserved from an early common ancestor and is key for successful biological function 
among multicellular organisms (NCBI 7042 2018; Wu and Hill 2009). 
 This heavy evolutionary conservation may further be in part to the type of cell 
signaling performed by the cytokine TGF-β2 (Wu and Hill 2009). TGF-β2 is associated 
with multiple cell functions including cellular growth (such as embryonic development, 
uterine maintenance, and wound healing), adhesion, apoptosis, and differentiation 
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(Heldin et al. 2009; Jung et al. 1994; Mir et al. 2015; UniProt P61812 2017; Wahl et al. 
2006; Wu and Hill 2009). Collectively, these developmental and signaling functions of 
TGF-β2 not only help to maintain the homeostasis of an organism, but also serve to 
encapsulate a recognizable biological “self” and maintain an organismal identity (Miller 
2018; Wahl et al. 2006; Wu and Hill 2009).  
This development and differentiation of “biological self” at a cellular level is 
what is critical to the establishment of an immune system, an independent system 
which is able to identify what is part of the self and what should be defended against 
(Miller 2018; Sadd and Schmid-Hempel 2009; Wu and Hill 2009). In this context, TGF-β2 
functions as immunoregulatory cytokine, maintaining the regulation and suppression 
of inflammatory responses as well as managing the development of regulatory T cells 
(Jung et al. 1994; Mir et al. 2015; UniProt P61812 2017; Wahl et al. 2006; Wu and Hill 
2009). Therefore, TGF-β2-induced immune responses are integral to the evolution and 
development of the individual immune system, pivotal to the development of both 
adaptive immunity as well as immune tolerance (Mir et al. 2015). 
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Immunity, however, is also strongly determined by evolutionary and ecological 
mechanisms (Miller 2018). Through the convergence of these mechanisms, ecological 
immunity is formed (Figure 2.1) (McDade 2012: Sadd and Schmid-Hempel 2009). By 
incorporating principles of evolution and life history theory, ecological immunity serves 
as an explanatory model for energetic exchanges across the life course (Lochmiller and 
Deerenberg 2000; McDade 2003; Sadd and Schmid-Hempel 2009).  
 
Life history theory centers itself on the notion of trade-offs, energetic concessions 
made between current and future biological processes (Hill and Kaplan 1999). The rules 
of energetics limit the input and output of energy; once resources are allocated towards 
something, they cannot be used for the maintenance of another biological system or 
Figure 2.1. Examples of variables which contribute and shape ecological immunity.   
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function (for example, personal growth and reproduction) (Hill Kaplan 1999; 
Lochmiller and Deerenberg 2000; McDade 2003; Sadd and Schmid-Hempel 2009). Most 
often life history theory is applied to questions regarding the timing of significant life 
events, such as growth, mortality, and reproduction, providing an evolutionary 
framework for how energetic trade-offs influence the timing of such events or impact 
the long-term health of an organism given how severe the trade-offs may be (Hill and 
Kaplan 1999). In other words, life history theory addresses Darwinian fitness and the 
problem organisms face of where to invest energy and when, and the positive and 
negative outcomes of the timing or intensity of those investments (Hill and Kaplan 
1999).   
Similarly, ecological immunity examines the effects of energetic choices in the 
development, maintenance, and use of the immune system (Lochmiller and Deerenberg 
2000; McDade 2003; Sadd and Schmid-Hempel 2009). Within the context of life history, 
immunity falls under energy directed towards growth (in developmental stages) and 
somatic maintenance (during use, upkeep, and recovery) (Hill and Kaplan 1999). Like 
other life history trade-offs, immunity comes with costs and takes resources to sustain 
(Lochmiller and Deerenberg 2000; Sadd and Schmid-Hempel 2009).  
Resource intake, however, is constrained by an organism’s environment 
(Lochmiller and Deerenberg 2000; McDade 2012; McDade 2003). The ability to create 
energy to subsequently invest is constricted by nutritional access and how much energy 
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is able to be inputted into an organism to create adequate output for biological 
processes (Lochmiller and Deerenberg 2000; McDade 2003). Quality of nutrition has 
been hypothesized to impact how the cost of functionality is mitigated, or even how 
well the immune system functions (Lochmiller and Deerenberg 2000; McDade 2003).  
The type of immunity can also vary the required energetic cost of upkeep 
(McDade 2003; Mir et al. 2015; Sadd and Schmid-Hempel 2009). Simple immune 
maintenance may require very little energy, but the development of adaptive immunity 
or using defensive immunity could cost a great deal, often at the loss of other fitness 
elements, such as reproduction (McDade 2003; Mir et al. 2015; Sadd and Schmid-
Hempel 2009). Ideally, an optimal immunity is reached, striking a balance between all 
fitness elements, and therefore allowing an organism to achieve maximum fitness and 
offspring quality (Hill and Kaplan 1999; Sadd and Schmid-Hempel 2009). To achieve 
optimal immunity, however, is dependent upon the pathogenicity of the environment 
of the organism and if there are enough available resources to counteract it (Lochmiller 
and Deerenberg 2000; McDade et al. 2016). Different environments and variability in 
resource access can create a selective pressure for certain types of immunity to prolong 
an organism’s life (Lochmiller and Deerenberg 2000; McDade et al. 2016). For example, 
ample nutrition and a high pathogen load favors immune effort to be funneled towards 
acquired or specific immunity, while insufficient levels of nutrition and a low 
pathogenic load favor innate or non-specific immunity (McDade et al. 2016).  
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It is important to emphasize that among humans the navigation of resource 
constraints, trade-offs, and environmental variables is not purely biological in nature. 
Our culture is – more often than not – incorporated into our environment, both 
structuring it and structure by it (Bourdieu 1980). Therefore, when examining the 
outcomes of human biology, it is valuable to consider our environment to be a 
biocultural one (Willey and Cullin 2016). For example, our cultural environment can 
play a very large role in the pathogens and parasites we may be exposed to or how we 
avoid them, such as the use of mosquito nets, agricultural techniques, and food 
preparation (Desowitz 1981). On a macro scale, our cultural environment can impact 
not only our exposure, but also how we access resources, with political borders, 
economics, ethnicity, religion, gender roles, and politics acting just as much of a 
hindrance as geographic impediments (Wiley and Cullin 2016).  
While this biocultural approach provides a holistic perspective of what ecological 
immunity consist of and what effects it, the significant population variation of 
ecological immunity often leads to the emergence of unique “ecological immunities” 
which reflect their biocultural environment. In this arena, emerging evidence indicates 
TGF-β2 may play a large role in defining ecological immunities.  
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TGF-β2 in Human Development and Immunity 
 The development of the human immune system begins early, both to create a 
separate immunological identity from the mother, and to help prepare infants for 
survival outside of the environment of the womb (McDade 2012; McDade 2003; Miller 
2018; Wu and Hill 2009). While human immunity is notoriously plastic, the 
developmental foundation is crucial, often shaping individual health throughout the 
life course (McDade 2012; Miller 2018). TGF-β2 plays an important role in the early life 
history of human growth and development, helping to facilitate the process of 
“biological self” identification for the fetus while also contributing tissue differentiation 
for organogenesis and bone growth (Miller 2018; UniProt P61812 2017; Wahl et al. 2006; 
Wu and Hill 2009). The process of “self” identification is furthered by the womb 
environment. Tissue biopsies show the placenta, secondly only to the prostate, has the 
highest rate of tissue-specific protein secretion of TGF-β2 in the human body which 
assists with maternal/fetus cellular differentiation and tolerance (NCBI 7042 2018; Wahl 
et al. 2006). Umbilical cord serum has also been shown to contribute to the development 
of fetal immune system in the womb, containing levels of TGF-β2 even greater that 
found in breastmilk (Agarwal et al. 2011).  
 In addition to being a barrier to separate maternal and fetal cells, the placenta 
also functions as an arbitrator for passive immunity to the fetus (McDade 2003). TGF-β2 
has been noted to facilitate the production of T cells and maintain immune homeostasis 
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in the placenta to help protect the fetus during development (Peng 2003; Shaarawy et al. 
2001; Wahl et al. 2006). It has also been found, however, that elevated levels of TGF-β2 
in maternal serum are linked with preeclampsia and eclampsia in humans (Peng 2003; 
Shaarawy et al. 2001; Wahl et al. 2006). Defects in TGF-β2 cell signaling during this 
critical fetal developmental period can lead to disease such as developmental defects of 
the cardiovascular system, Persistent Müllerian Duct Syndrome (PMDS), Marfan 
syndrome (MFS), Loeys-Dietz syndrome 4 (LDS4), abnormal scarring, as well as 
developmental defects and early cell death of the long bones and digits (UniProt P61812 
2017; Wu and Hill 2009).  
 
 TGF-β2 in Human Milk 
 After birth, infants continue to receive TGF-β2 from their mothers via breastmilk 
(Penttilä 2010). Evolutionarily, breastfeeding has been proven to be an efficient 
mechanism by which mammals may continue to provide nutrients and immune 
protection to infants after birth (Newburg 2001). Though energetically costly to the 
mother, lactation provides a vehicle for passive immunity to lay the groundwork for 
immune function throughout the extended childhood and adolescent growth period 
that humans experience (Newburg 2001). This is achieved through the transmission of 
several immunoregulatory cytokines and bioactive modulators which combine to make 
breastmilk a predominantly anti-inflammatory substance (Baumgartel et al. 2016; 
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Kuzawa et al. 2012; McDade 2003; Miller 2018; Miller and McConnell 2015; Miller and 
McDade 2012; Oddy and McHahon 2011; Penttilä 2010). 
After the discovery of TGF-β2 in human breastmilk roughly a quarter of a 
century ago, it has since been learned that TGF-β2 is the most abundant cytokine found 
in breastmilk (Ballard and Morrow 2013; Miller 2018; Saito et al. 1993). It has been 
found, however, that there is notable population variation in concentration of TGF-β2 in 
breastmilk (Filteau et al. 1999; Joseph et al. 2014; Miller 2018; Munblit et al. 2016; 
Penttilä 2010; Ruiz et al. 2017; Tomicic et al. 2010). This population variation of TGF-β2 
has been linked to differences in ecological immunity conditions, such as variation in 
disease or parasite load, history of pathogen exposure, chronic inflammation, resource 
access, weight, as well as cultural divides among population-dependent racial or ethnic 
groups (Baumgartel et al. 2016; Filteau et al. 1999; Joseph et al. 2014; Miller 2018; Miller 
personal communication; Munblit et al. 2016; Ruiz et al. 2017; Tomicic et al. 2010). For 
example, mothers who take probiotic supplements while breastfeeding as well as 
mothers who are overweight tend to have depressed levels of TGF-β2 in their milk 
(Baumgartel et al. 2016; Böttcher et al. 2008; Oddy and McHahon 2011). Coincidentally, 
those who took probiotics during their pregnancy are also found an increase in 
breastmilk IgA and TGF-β1, an isoform of TGF-β2 (Prescott et al. 2008). In sum, 
concentrations of TGF-β2 in breastmilk – and the efficacy of its immunoregulatory 
function – are environmentally and population dependent (Miller 2018).  
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Once ingested, breastmilk TGF-β2 continues to promote organ development, 
growth, and tissue homeostasis within the infant (Heldin et al. 2009; Ogawa et al. 2004; 
Penttilä 2010). Immunologically, TGF-β2 initiates the production of immunoglobulins, 
specifically IgA – an antibody which regulates immune function of mucosal membranes 
– as well as the production of T cells which act as the first defense of innate immunity 
(Agarwal et al. 2011; Ogawa et al. 2004; Penttilä 2010). It is a question of trade-offs, 
however, if high or low levels of TGF-β2 are desirable in breastmilk.  
Depressed levels of TGF-β2 in breastmilk have been found to be associated with 
a reduced incidence of infant eczema and less immune sensitization, indicating that 
lower levels of TGF-β2 in breastmilk lead to a decrease immune system sensitivity 
(Agarwal et al. 2011; Böttcher et al. 2008). This is beneficial in potentially regulating an 
oversensitive immune system which may result in chronic inflammation from the 
overproduction of antibodies in response to an antigen (Donnet-Hughes 2000).  
Conversely, in environments where atopic dermatitis, asthma, and allergies are 
frequent, elevated levels of TGF-β2 breastmilk have been linked to a reduction of these 
conditions (Agarwal et al. 2011; Oddy and Rosales 2010; Penttilä 2010; Ruiz et al. 2017; 
Tooley et al. 2009; Verhasselt 2010). It has been hypothesized that the reduction in these 
conditions is due to the mediation of the antigen in question through TGF-β2, the 
immunoregulatory cytokine allowing a level of immune tolerance to develop when 
exposed to small-dosed interactions with antigen agents (Penttilä 2010; Tooley et al. 
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2009; Verhasselt 2010). TGF-β2 also plays a large role in preparing the infant 
gastrointestinal tract immunologically, helping infants develop oral tolerance to solid 
food and antigen exposure, immune regulation of the mucosal surfaces of the body, 
foster a healthy beginning to infant gut bacteria, strengthen the intestinal barrier, as 
well as protect the intestine from inflammation and scarring during post-womb 
development (Hering et al. 2011; Maheshwari et al. 2011; Mir et al. 2015; Oddy and 
McHahon 2011; Oddy and Rosales 2010; Penttilä 2010). More research is needed on 
TGF-β2 and its interaction with the microbiome to further illuminate our evolutionary 
symbiotic relationship with gut bacteria and how it coincides with our immune system.  
 
TGF-β2 in Bovine Milk: Biocultural Crossover 
Just because we are biologically outfitted to breastfeed does not guarantee that 
we will. Humans employ a multitude of feeding tactics to nourish their offspring, be it 
the early inclusion of solid food, formula use, or substituting breastmilk for other milks 
(Martin 2018; Thompson 2013; Thompson et al. 2009). These feeding choices and styles 
impact not only the growth of the infant, but also their immune development.  
The consumption of other mammalian milks is almost entirely a uniquely human 
trait. Humans have an extensive history with milk consumption, one which stretches 
back so far that it has left a genetic mark upon our DNA in the form of lactase 
persistence (Ségurel and Bon 2017; Wiley 2014). There is evidence that this 
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incorporation of non-human milk into the infant diet may have been evolutionarily 
driven (Martin 2018). The flexibility of breastfeeding in humans is argued to allow for 
energetic trade-offs which allows mothers to have some control over where energy is 
allocated; complementary feeding, mixed feeding, and other lactational strategies are all 
outlets for additional energy resources for infant nutrition which are not solely reliant 
upon the maternal energy stores (Martin 2018). Non-human milk is an excellent 
resource for this strategy (Wiley 2014). The type of non-human milk integrated into an 
infant diet, however, tends to be driven by culture, whether it is for ceremonial 
purposes, availability of resources, ability to personally express milk, tradition, or from 
the impact of product marketing (Wiley 2014).  
When quantifying TGF-β2 milk, however, it is important to recognize that the 
concentrations of TGF-β2 in non-human milks may not always equate to what is found 
in breastmilk. In cow’s milk, the concentration of TGF-β2 is higher than that in human 
milk (Pakkanen 1998; Rogers at al. 1996). The reason for this unclear. One hypothesis for 
this could be that TGF-β2 is actively secreted in bovine milk while it is still 
undetermined if TGF-β2 in actively or passively secreted in human milk (Agarwal et al. 
2011; Rogers at al. 1996).  
What is known is that bioactive TGF-β2 from bovine milk is highly absorbable by 
the human intestine (Purup et al. 2006). Due to this cross-reactivity of the cytokine, the 
TGF-β2 found in cow’s milk is also found to have protective immunological effects on 
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the mucosal surfaces of the human gut (Russ et al. 2010). Like human milk, however, 
the concentration of TGF-β2 in cow’s milk diminishes over time, beginning at high 
concentrations in colostrum and slowly reducing overtime as nursing continues 
(Agarwal et al. 2011; Pakkanen 1998; Purup et al. 2006; Rogers at al. 1996). Therefore, 
how much bovine TGF-β2 is absorbed by the infant is often dependent upon when the 
cow’s milk is collected (Purup et al. 2006). Given this variation, it is key for researchers 
to note “time of collection” of samples as it may have important bearing on the 
concentration of TGF-β2 collected and may contribute to variation in results.  
  
Need for Anthropological Research: Evolution and Health  
 Early environmental exposures and life history events shape human immunity, 
be it trade-offs between innate and acquired immunity or resource allocation towards 
somatic effort or reproduction (Georgiev et al. 2016; McDade 2012; Oddy and McMahon 
2011). Research has shown that immunity and inflammation are beginning to show 
multigenerational effects (Kuzawa et al. 2012; McDade 2012; McDade et al. 2012; Miller 
2018; Miller et al. 2017). The immunity of offspring has been shown to be shaped by 
maternal pathogen and biological exposures as well as psychosocial stressors, all of 
which can lead to chronic inflammation which in turn can cause low birthweight and 
developmental damage to the fetus (Kuzawa et al. 2012; Miller 2018; Miller at al. 2017). 
It is hypothesized that this chronic inflammation experienced during pregnancy may 
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continue to be present in the infant after birth (Kuzawa et al. 2012). It is further 
hypothesizes that this chronic inflammation may also cause changes in immune 
programing in utero (Kuzawa et al. 2012).  
 As chronic and inflammatory disease rates continue to globally rise, so does the 
need to learn more about the ecological and evolutionary processes which effect the 
developmental processes of immunity (McDade 2012; WHO 2005). TGF-β2 is critical for 
operational immune development and growth in infants, as well as sustained, 
functional immunity in adults (Oddy and Rosales 2010). Therefore, TGF-β2 has the 
potential to be a promising biomarker for the study of chronic inflammation. Evidence 
has shown that measurement of TGF-β2 concentrations in breastmilk provides a good 
measure of subclinical, and potentially chronic, maternal inflammation (Filteau et al. 
1999).  
Cytokine signaling through breastmilk has been found not only to go from the 
mother to the child, but also vice versa (Miller 2018). Preliminary evidence has found 
that through both the medium of milk and saliva, infants can produce responsive 
immune signaling to the mother (Miller 2018).  
Expanding research on TGF-β2 in breastmilk could offer insight into population 
dependent ecological immunity, immunoregulatory development, and effects of 
chronic inflammation on human reproduction, growth, and disease for both mothers 
and infants. In turn, these results could illuminate some of the possible evolutionary 
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and ecological causal elements of chronic disease as well as inform intervention 
procedures.  
Within anthropological research, however, very little has been done with this 
cytokine. The goal of this thesis is to contribute to the understanding of TGF-β2 within 
in biocultural context and to foster continued research in this area of immunological 
study. Given the population variability of TGF-β2 concentrations in breastmilk and its 
dependency upon environmental factors, research across multiple populations will 
need to be done to represent the diversity of TGF-β2. Questions that need to be asked 
are: Is there an optimal range of TGF-β2 in breastmilk? Is there more variation of TGF-
β2 in breastmilk beyond the declining trajectory as nursing continues? What are the 
health outcomes of outlying TGF-β2 concentrations? A multi-population approach to 
these questions could illuminate some of the answers.  
 
Field-Friendly Methods in Anthropology 
Field-friendly methods have been an important part of anthropological research 
across all four subfields. In biological anthropology, these methods often provide a 
more convenient sample collection process for participants, allowing them to stay in an 
environment they are comfortable in, such as their homes, while the sample is taken 
(McDade et al. 2007). Field-friendly methods in biological anthropology are also often 
associated with the preservation and transportation of biological samples or materials 
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collected from study participants. The maneuverability and flexibility of these methods, 
however, are dependent upon the biological sample being collected and the 
environment in which it is being stored (McDade et al. 2007).  
Because of this, field-friendly methods are often defined by their ability to 
weather variable storage conditions, for example if consistent refrigeration is not an 
option. Drying biological material has proven repeatedly to be a field-friendly method 
for sample collection, particularly for serum (McDade et al. 2007; Miller and McDade 
2012). Dried blood spot (DBS) sampling has been shown to be an effective field method 
for a variety of biological markers, including immunoregulatory cytokines (McDade et 
al. 2007; Miller and McDade 2012). DBS is relatively non-invasive for participants – a 
simple finger prick is all that is needed to collect the sample – and allows for easier 
transportation than test tubes once dried onto paper cards (McDade et al. 2007). DBS 
samples do not require a constant cold chain and, once in the laboratory, can be frozen 
to remain stable for an extended period of time for continued analysis (McDade et al. 
2007).  
This method of drying biological material on cards has also been extended to 
breastmilk (Miller et al. 2013). Dried milk spotting has, so far, been found to be 
successful for the analysis of immunoglobulin IgA as well as the fatty acid content of 
breastmilk (Jackson et al. 2016; Miller at al. 2013; Miller and McConnell 2011; Rudolph 
et al. 2016). Though it has not been extensively tested in the field, a second field-friendly 
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methodology for milk analysis is the MIRIS Human Milk Analyzer, a battery powered 
machine which allows for the calculation of milk energy and macronutrients within a 
sample with no need for later sample analysis in a laboratory (Miller et al. 2013).  
For this thesis, however, I will be exploring the application of the dried milk 
spotting method for the analysis of TGF-β2 in breastmilk. In this endeavor, this is thesis 
is applied biological anthropology. In order to conduct a multi-population approach to 
answering the aforementioned research questions about TGF-β2, researchers may be 
faced with difficulties in collecting samples from remote or difficult to access regions. 
Given that the people who sometimes live in these regions are often those most at risk 
for exposure to chronic inflammatory catalysts (e.g. contaminated water, unsanitary 
waste disposal, reduced access to healthcare, etc.), these populations should be a 
priority for study. Sample collection and storage in conditions in these regions can be 
unpredictable, uncertain weather and access to electricity posing problems for sample 
preservation. Therefore, the dried milk spotting method appears to aptly lend itself to 
future research of TGF-β2 in breastmilk.  
When so much of biological anthropological research is often centered on some 
aspect of human variation or diversity, field-friendly methods are critical for 
researchers to gather data from multiple populations. Often, field-friendly methods 
help make sample donation easier for participants as well as keep samples stable as 
they await analysis. However, the current available field-friendly methods for different 
26 
 
biological substances and biomarkers is somewhat limited. In response to this and the 
potential challenges of field conditions, the next chapter will explore a new 
methodology for the storage, transport, and laboratory analysis of TGF-β2 in 
breastmilk.   
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CHAPTER THREE: 
METHODOLOGY 
 
 This chapter reviews the development of the methodology used for this thesis. I 
begin with a summary of current field-friendly methods for the storage and analysis of 
biological samples. Applying these methods in a laboratory setting, I then discuss the 
development of my original method from the results of my experimentation of methods 
found in the literature. The protocol for my finalized method is then outlined as well as 
the process of the assay validation for this new method.  
 
Current Methods in the Literature  
 The preservation and storage of biological fluids for cytokine analysis have been 
approached in multiple ways. Freezing samples has often proved to be the optimal 
method for this (McDade et al. 2007). This method protects samples from degradation, 
as well as allows for samples to be kept for an extended period of time before analysis. 
When maneuvering the obstacles of fieldwork, however, freezing samples is not always 
a feasible option for researchers.  
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 Because of this, many researchers have turned to drying biological fluids as a 
way of preserving their samples for cytokine analysis. One such method is known as 
DMS, or dried matrix spotting (Zheng et al. 2016). In this method, biological fluid is 
spotted in small quantities onto a paper card and allowed to dry (Zheng et al. 2016). The 
card is then packaged away in a plastic, airtight bag and then preferably refrigerated 
(Zheng et al. 2016). When it is time to conduct the laboratory analysis, punches are 
taken out of the card where the biomaterial has been spotted and then reconstituted 
with an elution buffer, a solution which assists with extraction of proteins from the 
paper (McDade 2014). The reconstituted samples are then run through the bioassay for 
analysis of a specific cytokine or biomarker of interest (Miller et al. 2015).  
 A bioassay is a biochemical analysis of the concentration of a specific bioactive 
substance within a solution, like TGF-β2 within breastmilk. A bioassay which is often 
used to measure protein concentrations within a biological matrix – such as breastmilk – 
is an ELISA assay. An ELISA assay is an enzyme-linked immunosorbent assay which 
uses antibodies, acids, and color change to detect specific biological substances. Samples 
are added to an antibody-coated 96 well, Maxi-Sorp plate which is prepared with 
capture antibodies the night before. A Maxi-Sorp plate is a flat rectangle made of 
polystyrene plastic with 96 small, individual wells which hold liquid samples. Once the 
samples have had time to bind to the capture antibodies on the bottom of the plate, a 
second set of antibodies are then applied on top of the sample. This process is known as 
29 
 
an ELISA “sandwich” assay. The two sets of antibodies which “sandwich” the sample 
specifically capture the protein or cytokine in question. The concentration of the 
captured protein is then measured via a microplate spectrophotometer. This 
spectrophotometer quantifies the color change of each sample in each well of the 
microplate which is activated by adding proteins to the top layer of antibodies.  
 These concentrations are then compared to a standard curve of concentration 
values (Figure 3.1). In ELISA assay kits, a concentrated standard with a known amount 
of analyte is provided. The researcher then creates the standard curve by diluting the 
standard through a two-fold dilution. This linear process of dilution forms a standard 
curve which encompasses the lowest and highest detectible concentrations of an analyte 
which can be accurately detected within the assay. The unknown concentrations of the 
samples are then measured by the standard curve. Generally, analyte concentrations 
from the tested samples are expected to fall in the mid-range of this curve.  
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The DMS method has been shown to consistently provide stable samples for 
accurate bioassay analysis for serum, saliva, or milk (Jackson et al. 2016; McDade 2014; 
Miller et al. 2015; Miller and McConnell 2011; Miller and McDade 2012; Rudolph et al. 
2016; Zheng et al. 2016). DMS has been heralded to be an incredibly researcher and 
participant-friendly method (McDade et al. 2007; Miller and McConnell 2011; Zheng et 
al. 2016). It does not require a great deal of sample be taken from the participant and the 
mobility of the method allows for samples to be collected outside of the laboratory 
setting (McDade et al. 2007; Miller and McConnell 2011; Zheng et al. 2016). It has also 
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Figure 3.1. Example of an ELISA standard curve generated from a spectrophotometer in the Health and 
Human Biology Laboratory at the University of South Florida.  
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been demonstrated that DMS does not necessarily require refrigeration to maintain 
sample integrity (McDade et al. 2007; Miller et al. 2013; Miller and McConnell 2011; 
Rudolph et al 2016). This in combination with being both low-budget in material costs 
and low maintenance for storage makes it a prime method for sample collection in the 
field (McDade et al. 2007; Miller et al. 2013; Miller and McConnell 2011; Rudolph et al 
2016).  
DMS has demonstrated great success with serum and saliva spotting (McDade 
2014; McDade et al. 2007; Miller and McConnell 2011; Miller and McDade 2012; Zheng 
et al. 2016). With DMS for milk, Miller and McConnell (2011) found success in drying 
milk spots on paper for immunoglobulin analysis, spotted samples able to be used for 
up to eight weeks once spotted onto the card. Rudolph et al. (2016) also found success 
with DMS for milk in measuring fatty acid composition, a result also found by Jackson 
et al. (2016).  
That being said, DMS is not without its limitations. The small volume of sample 
is convenient for participants, but can a potential limitation for researchers, especially 
when working with serum (McDade et al. 2007). Milk that has been spotted does 
experience some loss of bioactive agents, such as cytokines, due to time and exposure to 
ambient temperatures (Miller et al. 2013). Lastly, use of DMS requires time for assay 
development and validation for the biomaterial used and the biomarker in question 
(McDade et al. 2007).   
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These limitations are important to consider when exploring field-friendly 
method options for research, not only when planning sample collection, but also the 
laboratory analysis. While the DMS method allows for samples to be dried, stored, and 
transported without a cold chain to preserve the samples, the gradual loss of the analyte 
of interest from the sample can influence the bioassay, the results registering lower 
levels of analyte than were initially present in the sample (Miller et al. 2013). This loss 
tends to occur over time as the sample itself begins to degrade, a process usually slowed 
by refrigeration or freezing (Miller and McConnell 2011). Various biomarkers have also 
been found to degrade at different rates, something which must be taken into account 
when choosing a method. 
The restricted volume of sample of the DMS method can also cause issues during 
laboratory analysis. In order to accurately run the bioassay, a certain threshold of 
sample is required to detect the unknown concentration of analyte in the sample. 
Without a large amount of sample to use for multiple rounds of laboratory analysis 
researchers are restricted in the number of tests they can conduct or the number of 
times they can test samples. For example, if samples were difficult to procure and 
laboratory analysis is expected to call for larger sample volumes for testing, then the 
DMS method – though field-friendly – may not lend itself to the needs of that particular 
study. These methodological limitations highlight once more the need for more friend-
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friendly methods within biological anthropology, specifically to address some of the 
shortcomings of the DMS method.  
 
Preliminary Evaluation of Storage Methods 
 DMS  
 When approaching the development for the storage, transportation, and analysis 
of TGF-β2 in breastmilk, the initial design was to use the DMS method, given its 
previous success in detecting other bioactive immune markers (Miller et al. 2013; Miller 
and McConnell 2011; Miller and McDade 2012). Using the methods described in the 
literature (Miller and McConnell 2011), I spotted 20µL of whole breastmilk which had 
been previously frozen onto DMS paper cards. Once spotted, the cards were left out to 
dry overnight and then packaged the following day in airtight, plastic bags with 
desiccant packets. Small rounds were punched out of the cards and reconstituted in an 
elution buffer of phosphate-buffered saline (PBS) with 1% bovine serum albumin (BSA). 
The paper rounds were soaked in the elution buffer for 30 minutes before being acid 
activated for application to the plate to be assayed.  
  However, this method failed to successfully extract TGF-β2 from the milk 
spotted on the cards. To confirm this result, I altered the method for the DMS protocol. I 
increased the number of punches in the elution buffer as well as adjusted the volume of 
milk spotted on to the cards. I varied the length elution and attempted acid activation of 
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the solution with and without the paper punches present in the solution. Following 
suggestions from the literature, I also experimented with adjusting the elution solution 
by adding the detergent TWEEN20 to the buffer (McDade 2013; Miller and McConnell 
2011; Zheng et al. 2016). Regardless of these modifications, significant levels of TGF-β2 
failed to be extracted.  
 In an attempt to pinpoint the barrier preventing the successful extraction of TGF-
β2 from the cards, I followed the method presented by Miller and McConnell (2011) to 
create a standard from a different matrix. The standard is critical to an assay because it 
provides a reference curve of known concentrations of a protein by which unknown 
amounts can be measured. Because the standard which came with the TGF-β2 assay kit 
was reading for concentrations much higher than what was being detected on the 
samples spotted on paper, I extrapolated from the method used by Miller and 
McConnell (2011) to develop a new method to create a new standard from spotted 
breastmilk as well as both bovine and soy based baby formula to compare my samples 
to.  
 While this method for new standard creation also proved to be unsuccessful, this 
line of experimentation did reveal that there are concentrations of TGF-β2 in bovine 
milk-based infant formula which are almost comparable to that found in human milk. 
This result was not found in the soy-based infant formula, nor in whole milk analysis of 
almond or soy milk.  
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 Polystyrene Plastic  
 Given that the paper seemed to somehow inhibit the extraction of TGF-β2 from 
the dried milk sample, I proceeded by exploring drying the milk in polystyrene plastic 
instead of on DMS cards. While I did not find any literature to support the efficacy of 
this idea, milk dried on glass had been proven to be a successful technique for 
extracting biomarkers ELISA assay analysis (Samsonova et al. 2017).  
 To echo this method, I dried small quantities of breastmilk on petri dishes 
overnight, the wide surface area allowing for expeditious evaporation to occur so the 
samples could be packaged the following day for storage (Figure 3.2). The dried milk 
sample from the petri dishes was able to be reactivated with reagent at a 1:1 ratio and 
assayed with the TGF-β2 ELISA. Results from the petri dishes indicated that the TGF-β2 
extracted from the dried sample left out overnight was comparable to the concentration 
of TGF-β2 found in the whole milk sample. The petri dish drying method was 
replicated with cow’s milk, goat’s milk, almond milk, soy milk, infant formula, and soy 
formula, samples which were purchased from the grocery store. Samples from each 
milk including breastmilk samples were dried on petri dishes and left out for three 
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days. The dried samples were then assayed, the results of which were compared to 
refrigerated, whole milk samples in the TGF-β2 assay.  
 
New Method 
Protocol  
The first aim of this thesis is the development of an original laboratory protocol 
for the field preservation and laboratory analysis of the cytokine TGF-β2 in human 
breastmilk. Breastmilk which was anonymously donated to the Health and Human 
Biology Laboratory was used for the development of this assay protocol. Given the 
anonymity of the donor, the lack of identifiers within the samples that could be traced 
Figure 3.2. Milks drying in polystyrene petri dishes in the Health and Human Biology Laboratory. 
Photo copyrighted to Chlöe Sweetman 2018.  
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back to her or her offspring, and the methodologically driven purpose of this thesis, IRB 
authorization for this study was waived (Appendix A).   
The donated breastmilk had been pumped on six different days over the span of 
two infants by one woman. These whole milk samples were kept frozen at the 
laboratory and thawed for the use of this study. It has been shown that the effects of 
freezing and thawing breastmilk do not affect the integrity of TGF-β2 in human milk, 
therefore this did not pose a limitation on the samples (Miller personal communication).  
Given the success of the petri dish pilot experiment, I choose to use 12-well non-
treated polystyrene microplates for the development of my protocol. These microplates 
were chosen because the wells were 3.8cm2 in diameter, large enough to spot greater 
quantities of sample onto the plate while still providing enough surface area for 
adequate evaporation to occur overnight. They are also small and light, easy to stack 
and transport in a field setting.  Once the breastmilk samples were thawed, 200µL of 
whole milk of each sample was pipetted in duplicate onto the 12-well microplate. Wells 
were labeled to indicate samples from various pump days (Figure 3.3).   
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Samples were left out overnight on the laboratory workbench to dry. The 
following day, industrial desiccant balls were added to the wells to absorb any 
remaining moisture and the plates were sealed their lids and tape (Figure 3.4). As many 
desiccant balls may be added to the wells as needed. I highly recommend the use of 
color changing desiccant balls so that you can see through the packaging when they 
research their maximum absorption (Figure 3.5). This acts as a convenient measure for 
when they need to be changed. The desiccant balls used for this protocol had the ability 
to be reused after washing and drying, but for the purpose of keeping samples distinct, 
only new desiccant balls were added into wells once old ones were removed.  
Figure 3.3. Dried breastmilk from various pump days on a polystyrene microplate. Photo 
copyright Chlöe Sweetman 2018. 
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Once the lids were taped on, the microplates were then placed in plastic bags 
with additional desiccant packets placed inside the bags (Figure 3.6). Microplates were 
then divided among four temperatures: ambient temperature atop the laboratory 
workbench, 35°C in the incubator, the refrigerator, and the freezer. Samples were left in 
their respective environmental conditions for three weeks, only moved when their 
desiccant needed to be changed. After the three week incubation period, samples were 
reconstituted with reagent diluent (PBS with 1% BSA) at 1:1 ratio. Microplates were 
placed on a plate shaker as they reconstituted, swirling for 30 minutes.  
 
Figures 3.3 and 3.4. Figure 3.4 (left) shows fresh desiccant added to microplate wells of dried 
breastmilk. Figure 3.5 (right) shows desiccant which has reached capacity of moisture and needs to 
be changed. Photos copyright Chlöe Sweetman 2018. 
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The reconstituted breastmilk samples were then analyzed for TGF-β2 
concentrations using the Human TGF-beta 2 DuoSet ELISA assay kit from R&D 
Systems (Catalog Number: DY302). The antibodies in the TGF-β2 ELISA assay kit are 
specifically designed to bind to the human TGF-β2 molecules in the milk samples. The 
R&D kit was chosen for this study because of its reliability and affordability.  
Once the breastmilk samples were reconstituted, the samples were then acid 
activated with HCL. After ten minutes, they were deactivated with NaOH and mixed 
with reagent diluent. Fifty microliters of each sample was then pipetted in duplicate 
onto the microplate to bind with the capture antibodies, along with 50µL of standard. 
The standard reagent was provided with the kit and reconstituted with reagent diluent. 
An eight point standard curve was then created using a two-fold serial dilution method 
Figure 3.6. Breastmilk samples dried on microplate, packaged, and ready for storage. Photo 
copyright Chlöe Sweetman 2018. 
41 
 
using the standard provided in the kit. Once plated, the standards and samples were 
incubated for two hours. After the incubation period, the second antibody – the 
detection antibody – was pipetted onto the plate and allowed to incubate for another 
two hours. The colorimetric components of the assay were added after the second 
incubation period. The full assay protocol can be found in the appendices (Appendix B).   
Acid was used to stop the biochemical reaction of the assay. The finished plate 
was then placed in the Epoch spectrophotometer which reads the colorimetric results of 
the assay using BioTek Gen5 software with a programing protocol for the TGF-β2 assay 
(Figure 3.7).  
  
 
 
Figure 3.7. Microplate waiting to be read by the spectrophotometer once the assay colorimetric reaction 
has been stopped. Photo copyright Chlöe Sweetman 2018.  
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Assay Validation  
 The second aim for this study is to validate this new protocol and the assay 
which was used. Assay validation is an essential component of assay protocol 
development; it substantiates if the new method can reliably perform and produce 
consistent results (McDade 2013; McDade et al. 2007). Assay validation is done through 
a series of tests which statistically measure the assay’s performance, including its 
accuracy, precision, and replicability (McDade 2013; McDade et al. 2007). Eight plates at 
half capacity were run for this study to include all the necessary tests for the assay 
validation.  
 Linearity of dilution. Testing for assay accuracy, one sample was diluted several 
times. The samples should cluster closely to a straight line of descending levels of 
concentration.  
 Spike and recovery. 200µL of sample was spiked with 5µL of standard before it 
was dried. The spiked sample was then compared to the concentration of an unspiked 
sample. The goal of this test is to recover the full amount of the spiked standard from 
the sample to test the effects of the sample matrix of the milk on the assay’s 
performance.  
 Intra-assay variation. Testing the precision of the assay, a single sample was 
pipetted multiple times across a single plate. Ideally, there should be very little 
variation among these samples; typical values for the percent coefficient of variation 
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(%CV) for an ELISA fall below 10-15%, with 10-15%CV being the upward limit of an 
acceptable range of variation between samples.   
Inter-assay variation. A single sample was pipetted multiple times across multiple 
plates to test the consistency and reliability of the assay. Again, there should be little 
variation between samples across plates with 10-15%CV being the upward limit of an 
acceptable range of variation between samples. This test can also be used as the controls 
for the assay, as was done for this study. In tandem with the standard, controls help 
further define the acceptable range of results within an assay.  
Lower limit of detection. Plain reagent diluent without the addition of any sample 
was pipetted onto a single plate multiple times to test the sensitivity of the assay by 
assessing the smallest quantity of analyte detectable by the assay. The threshold of the 
lower limit of detection is three standard deviations above the mean of these zero 
values.  
Stability tests. Stability of the TGF-β2 in the dried breastmilk samples in the 
different environmental conditions were compared a baseline sample, dried milk 
samples from the freezer (McDade 2013). Room temperature, incubator, and 
refrigerator samples within a 10% coefficient of variation (CV) range of the freezer 
samples are regarded as stable (McDade 2013). Samples used to test stability were all 
run on the same plate minimize error. 
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Method comparison. A Bland-Altman plot will test if the results of the dried milk 
method yields results comparable to the whole milk samples. A linear regression was 
run to confirm or reject the significance of these results with α = .05. This statistical 
analysis was chosen because it measures the actual slope of the relationship between 
two continuous variables rather than the standardized slope.  
Multi-milk analysis. TGF-β2 was assayed from human, bovine, goat, and bovine-
base infant formula milks, both in dried (three days) and whole milk form. 
Concentrations of TGF-β2 from the different milks were then compared, the results of 
which are discussed in the following chapter.  
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CHAPTER FOUR: 
RESULTS 
 
Aim One Results 
 The dried matrix spotting (DMS) method (Zheng et al. 2016), which had been 
ratified by the current literature as a promising field-worthy method, unfortunately, 
failed to allow for the successful extraction of TGF-β2 once the milk had been dried on 
the paper. Drying milk on polystyrene proved to be a viable substitute for the 
development of this protocol.    
 
Aim Two Results 
The stability of the dried milk method was measured by comparing the 
coefficients of variation (CV) of the dried milk left at ambient, 35°C, and refrigerator 
temperatures to the baseline CV of the dried milk samples that had been placed in the 
freezer. Results showed that samples left at ambient room temperature and in the 
refrigerator for three weeks were within a 10% CV range of the baseline samples in the 
freezer, indicating that these samples were stable for analysis (McDade 2013). Half of 
the samples that has been placed in the incubator at 35°C for three weeks, however, fell 
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outside of the 10% CV range, indicating that dried milk samples exposed to hot 
environments for an extended period of time will begin to degrade.  
The concentrations of the TGF-β2 found in the various samples kept at different 
temperatures were used to create a Bland-Altman plot. A Bland-Altman plot provides a 
graphical comparison of two methods to show if they are comparable; in other words, if 
the outcomes of two different methods are in agreement and could potentially be 
interchangeable (Bland and Altman 1986). In this study, a Bland-Altman plot was made 
to compare if the results from dried milk samples from all four environmental 
exposures would be equivalent to their whole milk counterparts and therefore if the 
two methods are potentially equivalent (Figure 4.1).  
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The results of the Bland-Altman plot show that the majority of dried samples fall 
within the 95% confidence interval (indicated by the red, dashed lines on the graphs), 
suggesting that dried milk on the polystyrene microplates is a comparable method to 
using whole milk samples. To confirm this finding, a linear regression was performed 
comparing the dried (dependent variable) and the whole milk (independent variable) 
Figure 4.1. A Bland-Altman plot showing the comparability of the dried milk method with the whole milk 
method for samples left at room, 35°C, refrigerator, and freezer temperatures for three weeks. The black line 
indicates the mean of the sample concentrations of TGF-β2. The red dashed lines indicate the upper and lower 
confidence intervals at 95%.  
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methods of analysis. The results of the linear regression indicate that the relationship 
between the between the dried and whole milk methods is statically significant at p = 
0.042 with an α = .05 (Table 4.1). This indicates that the two methods are comparable to 
one another. It should be noted, however, that the R² for this regression was 0.147, 
which is very low. This is due to the large range of results from the assay, indicating 
that this assay may struggle with precision when using the dried milk method.  
 
Table 4.1. Linear Regression of dried versus whole milk samples.* 
      95% Confidence Intervals for b 
Unstandardized regression 
coefficient (b) R² P-Value Lower Bound Upper Bound 
0.764 0.147 0.042 0.028 1.499 
          
*α=.05. 
 
The assay’s accuracy was measured by the linearity of dilution. A single sample 
was diluted four times through two fold dilution and the concentrations were plotted 
via a scatter plot (Table 4.2). Ideally, the diluted samples should cluster along a straight 
line, with an R² as close to 1 as possible. As can be seen in figure 4.2, the linearity of 
dilution for this study has an R² = .993. This indicates that this assay is effectively able to 
detect TGF-β2 within the natural sample matrix of milk of the dried milk (Thermo 
2007).  
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Table 4.2. Linearity of Dilution ratios and concentrations.*  
Dilution Ratios TGF-β2 Concentrations 
1.00 676.0773 
0.50 277.587 
0.25 84.8502 
0.125 27.5859 
0.0625 6.4368 
*Concentrations pg/mL. 
 
 
Similarly, spike and recovery measures the effect of the sample matrix on the 
assay’s performance. Five microliters of standard was spiked into 200µL of sample 
Figure 4.2. The linearity of dilution of a single dried milk sample.  
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before it was dried for six different samples. The recovery for the spiked samples was 
119% within the R&D TGF-β2 assay. Contrary to the linearity of dilution test, this high 
recovery rate points towards the matrix of the reconstituted dried milk samples 
interfering with assay’s ability to accurately identify the analyte.  
The percent coefficient of variation for the intra-assay variation was 38.28%. The 
standard acceptable CV for this assay is usually set at 10%, though it may be extended 
to 15% in extenuating circumstances (Miller and McConnell 2011). This extraordinarily 
high CV for the intra-assay variation calls into question the precision of this assay when 
using dried milk samples given that there is so much variation within one sample 
pipetted multiple times across one plate. The percent coefficient of variation for the 
inter-assay variation was also high at 17.70%. This variation between a single sample 
pipetted across multiple plates indicates that this assay is facing similar troubles with its 
ability to perform consistently and reliably with dried milk samples.  
Lastly, the lower limit of detection (LLD) for this assay was 39.7807 pg/mL. This 
does not bode well for the assay’s sensitivity given that this LLD score is above the 
lowest standard within the standard curve for this assay. The lowest level of the 
standard curve should signify the smallest detectable quantity within the assay. This 
result implies the lowest quantity of analyte detectable within this assay is above the 
lowest standard, indicating that the full concentration of the analyte within the matrix 
may not be being read in this assay.  
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Aim Three Results  
 The detection of TGF-β2 in the bovine and goat milk was not surprising given 
the evolutionary conservation of TGF-β2 in metazoan; by proxy, nor was the presence 
of TGF-β2 in bovine milk-based infant formula (NCBI 7042, 2018; Wu and Hill 2009). 
Table 4.3 presents the similarities and differences of TGF-β concentrations in the various 
milks tested.    
Table 4.3. Concentrations of TGF-β2 in an assortment of milks.*  
Human Milk Concentrations (pg/mL) 
Whole Milk Mean SD Dried Milk Mean SD 
313.99 613.72 347.70 455.18 880.72 580.14 
283.87     224.09     
1131.19     1661.79     
838.38     1181.80     
548.76           
391.90           
Bovine Milk Concentrations (pg/mL) 
Whole Milk Mean SD Dried Milk Mean SD 
4268.40 4193.19 201.02 4809.36 4693.33 255.93 
4117.96   4577.30   
Goat Milk Concentrations (pg/mL) 
Whole Milk Mean SD Dried Milk Mean SD 
1080.09 1051.29 49.68 1077.95 1051.66 71.41 
1039.53     1111.82     
Bovine Milk-Based Formula Concentrations (pg/mL) 
Whole Milk  Mean SD Dried Milk Mean SD 
1465.36 1545.44 210.69 556.72 416.75 143.18 
1665.48     411.25     
*TGF-β2 concentrations are in pg/mL. Dried samples were left out, uncovered at ambient temperature in the 
laboratory for three days before analysis. Non-human milks were purchased at the grocery. 
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Of the whole milk samples, human milk and goat milk have the most similar 
concentrations of TGF-β2. Bovine milk has, by far, the largest concentration of TGF-β2. 
The TGF-β2 in bovine milk-based infant formula (BMB) appears to be slightly higher 
than the concentrations in human milk. When compared to bovine milk, however, the 
concentrations within BMB infant formula are remarkably low, only a fourth of what is 
found within bovine milk. Given that BMB infant formula is created largely in part from 
bovine milk to mimic to effects of breastmilk, this disparity in TGF-β2 is noteworthy.  
BMB infant formula continues to perform curiously when dried. TGF-β2 has 
been demonstrated to be a hardy cytokine, maintaining its biological integrity in 
various temperature conditions (Miller, personal communication). This is also seen in 
Table 4.3, where the mammalian milks appear to experience very little degradation in 
their three day drying process. BMB infant formula, however, seems to degrade at a 
much faster rate. The implications of these results are discussed in the following 
chapter. 
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CHAPTER FIVE: 
DISCUSSION 
 
Aim One 
 The results pertaining to the first aim of thesis appear to be promising. The 
protocol using the new polystyrene drying method was successful developed and has 
the potential to be a field-friendly method. The use of the color changing desiccant balls 
brings to light that humidity may be an important factor to consider in sample storage 
for fieldwork. While it is currently unknown the extent to which humidity may impact 
biological samples that have been dried and stored, the desiccant balls changed color 
over a period of six to seven days on average – faster for the incubator samples and 
slowest for the freezer samples. This observation is definitely noteworthy for future 
research and may need to be further pursued to understand its full effects.  
 
Aim Two 
 The results of the second aim of this study failed to validate the use of the 
Human TGF-beta 2 DuoSet ELISA assay kit from R&D Systems with the newly 
developed storage method of drying milk on polystyrene plates. Though this assay kit 
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was compiled specifically for immunoassay development and validation, the assay 
validation tests uniformly presented results which raised doubts about the assay’s 
accuracy, precision, reliability, consistency, and replicability for the intent of study.  
That being said, the linear regression analysis comparing the dried milk and the 
whole milk methods indicate that the two methods are potentially interchangeable to 
achieve the same outcomes. Unfortunately, the power of this test is relatively low due to 
the low small sample size. Because of this, the results of the linear regression analysis 
can only tentatively support the viability of the protocol developed in this study for this 
assay.  
The limitation of the small sample size was partially due to sample loss during 
the study. The damage caused by hurricane Irma created widespread power outages 
across Florida and, with them, four of the samples prepared for donation were ruined 
and had to be discarded.  
The three outliers in the Bland-Altman plot also raises an issue with experiment. 
The outliers are the same sample across three different temperatures exposures. While 
TGF-β2 concentrations are known to be highly variable across populations and even 
within individuals, it seems unlikely human variation was the cause of these outliers. 
To investigate, I re-ran the outlying sample from the 35°C batch of mircoplates from a 
newly reconstituted plate the following day. The initial outlier had a TGF-β2 
concentration of 2359.33 pg/mL; when re-run, the same sample from a different 
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microplate had a concentration of 421.99 pg/mL, a value well within the 95% confidence 
interval.  
This variation could have resulted from a variety of sources. Most likely, it is due 
to researcher error, perhaps insufficient reconstitution of samples or potentially 
inadequately shaken liquid whole breastmilk samples before being pipetted on the 
microplates to dry. This error, however, could also be due to the issues with the assay 
itself.  
The assay kit and all reagents, buffers, and solution used in this study were 
freshly purchased or within their expiration date. Again, operator error may be to 
blame, such as inability to completely remove all wash buffer from the plates before 
adding assay materials, pipetting mistakes, or potential cross contamination of different 
samples.  
 Given the widespread inconsistency of the assay, however, I suspect the root of 
the problem may lie with the interference of the matrix of the reconstituted dried milk 
samples on the assay’s ability to properly perform to fully detect concentrations of TGF-
β2. This hypothesis appears to be supported by the literature and the variation in the 
results themselves. Firstly, where dried samples would be assumed to contain smaller 
quantities of TGF-β2, they sometimes presented concentrations which were greater than 
the whole milk samples. Evidence of this can be seen in Table 4.3 and the spike and 
recovery rate of 119%.  
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Secondly, While it is known that there is individual and population variation of 
TGF-β2 in breastmilk, the concentrations of TGF-β2 in the whole milk samples from this 
study appear to be markedly lower than those which have been reported in the 
literature with an average TGF-β2 concertation of 592.85 pg/mL (with a range of 220.52-
1205.90 pg/mL). TGF-β2 concentrations sampled from populations in California and 
Washington in the United States have been found to have an average concentration of 
1600 pg/mL (with a range of 1000-2400 pg/mL) and 1430 pg/mL (with a range of 850-
2290 pg/mL), respectively. While the breastmilk for this thesis came from a single 
individual and not a population and these reduced concentrations maybe due to human 
variation, this evidence may indicate not only that the assay used for this study in 
incompatible with the developed protocol, but it may also be struggling to fully read 
the true concertation of the TGF-β2 in the samples.  
 
Aim Three 
 The TGF-β2 biosimilarities in the mammalian milks and the bovine milk-based 
infant formula (BMB) engender intriguing questions about human health and the 
biocultural effects on multi-milk consumption. The biosimilarities of assayed milks was 
picked up due to cross-reactivity within the assay. Cross-reactivity is when biological 
substances of one species achieves similar biological effects within another. As 
previously discussed in chapter two, it is known that TGF-β2 from bovine milk does 
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successfully proliferate human intestinal cell for absorption and is biologically used by 
the human body for immunological maintenance and development (Purup et al. 2007; 
Russ et al. 2010). The extent to which the bovine TGF-β2 is absorbed by human 
intestines is in need of further investigation.  
 In turn, this raises the question about the extent to which TGF-β2 in BMB infant 
formula is absorbed. TGF-β2 remains bioactive in BMB infant formula, as was seen in its 
cross-reactivity with the assay in this study. Animal models have shown, however, that 
BMB infant formula which is not supplemented with additional TGF-β2 tend to have 
increased rates of inflammation and allergy responses (Penttilä 2010; Tooley et al. 2009). 
This indicates that the amount of TGF-β2 in BMB formula alone is not enough to help 
the infant immune system fully develop.  
This raises intriguing questions about human growth and development given 
that it appears BMB formula, on average, tends to have a higher concentration of TGF-
β2 than human breastmilk. Perhaps this difference in grow and immune development 
in breastfed and formula fed infants is due to other bioactive or microbial variables. It is 
also important to consider that variation in feeding frequency between breastfeeding 
and formula feeding may be linked to this difference as well.  
 What has been learned from this thesis is that, compared to whole bovine milk 
from which BMB infant formula is developed from, the concentrations of TGF-β2 in 
BMB infant formula are acutely reduced. This reduced concentration of TGF-β2 may be 
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due to the preservation and packaging processes formula goes through in preparation 
for consumer consumption, such as extreme heating and dehydration (Haug et al. 2007). 
The survival of TGF-β2 in formula after the drying process, however, does bolster the 
potentially viability of the polystyrene drying method developed for this study.  
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CHAPTER SIX: 
CONCLUSION 
 
 This thesis began with three aims: to develop a new protocol for the field and 
laboratory storage and analysis of TGF-β2 in human breastmilk, to validate this new 
protocol and the assay used, and to explore the potential health effects of TGF-β2 via a 
multi-milk method. While the new protocol and polystyrene drying method hold 
potential for future development and use, there is still work to be done to hone and 
refine this method. The validation of the TGF-β2 ELISA assay kit was unsuccessful, 
indicating that this assay is not compatible with developed protocol as it currently 
stands. However, results of the linear regression analysis and stability analysis indicate 
that the storage method of drying milk on polystyrene is a potentially viable method as 
it is both stable and provides results comparable to whole milk samples. Lastly, the 
finding of biosimilar TGF-β2 in bovine, goat, and bovine milk-based infant formula 
(BMB), while not wholly novel, did find new information about the resilience and cross-
reactivity of TGF-β2 through this study’s multi-milk analysis.  
 
 
60 
 
Applications and Future Research 
 This thesis has highlighted a continued need for the expansion and innovation of 
field-friendly methods for the collection and storage of biological materials. The 
development and validation of these methods takes time, but as more is revealed about 
the complexities of human health and growth, the more important these methods 
become to learn about human variation in immunity and development.  
 Field-friendly methods for the storage and analysis of breastmilk seem to be the 
next frontier for human biology, especially as a focus within applied biological 
anthropology. As previously discussed, breastmilk has emerged to be a very popular 
focus of research in biological anthropology over the past decade, partially because of 
the ease with which it can be collected and partially because of the extensive biological 
information it can provide. While breastmilk is easy to collect, field-friendly methods 
for storage and transportation have yet to be developed outside of adapting previous 
methods used for other biological substances, such as serum or saliva. In order to 
advance breastmilk research, these field-friendly methods will need to be developed so 
greater swaths of human biological diversity can be included in these studies.  
As was shown in this study, however, all methodologies cannot be universally 
applied to the collection of all or any biomarkers of interest. Therefore, as human 
biology research becomes increasingly specific in its research focus upon biological 
drivers behind different aspects of growth and development, so too must the methods 
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we use. To truly assess the performance of the protocol developed for this thesis, more 
experimentation needs to be done. Firstly, the time recommended to reconstitute the 
samples needs to be extended. While the plate shaker helped expedite this process, it 
appears that the samples may require more time to be fully returned to a workable 
liquid form. It was noted during this study that fat from the milk sometime hindered 
the workability of the reconstituted samples. In future work, consideration for 
centrifuging the samples to separate the whey from the fat before acid activation may 
prove fruitful. Lastly, a larger sample size would improve the statistical evaluation of 
the viability of this protocol. Given the failure to validate this assay for the new 
protocol, however, I would recommend that a different assay be used in the future 
development and analysis of the polystyrene dried milk method.  
 The results of this study prompt the need for more research, not only in method 
development, but also in regard to TGF-β2 in human health and growth. In BMB infant 
formula, the diminished concentration of bovine TGF-β2 has been demonstrated in 
animal models to be insufficient for the optimal development of an early immune 
system (Penttilä 2010; Tooley et al. 2009). This raises questions about the long-term 
health effects which BMB infant formula may have on human growth and health.  
Additionally, the rapid decay rate observed of the re-dried BMB infant formula 
(Table 4.3) could foreshadow an issue with the stability of the TGF-β2 in formula once it 
has been reconstituted. While formula guidelines direct users not to store reconstituted 
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formula and to throw out prepared formula if not used with a one hour period, many 
families do not follow these guidelines for a variety of reasons, though economic 
concerns probably rate chief among them. Infants who consume stored reconstituted 
formula are therefore probably absorbing even less TGF-β2 than the already inadequate 
quantities found in freshly made formula, putting them at risk for negative health 
outcomes.  
TGF-β2 in milk has been shown to influence growth trajectories. Wiley’s work 
(2014, 2009, 2007, 2005) has thoroughly explored the effect of bovine milk on children’s 
growth, finding that early consumption of cow’s milk contributes to improve height 
outcomes. While the TGF-β2 in milk, both bovine and human, is definitely involved in 
positive growth outcomes, it is not solely responsible for them (Miller personal 
communication; Purup et al. 2007; Russ et al. 2010). Instead, it is hypothesized that 
consumption of TGF-β2 in tandem with the other bioactive elements, such as IGF-1, and 
nutrients in milk combine to create these growth outcomes (Miller personal 
communication; Purup et al. 2007).   
Given the influence the potential influence TGF-β2 from bovine milk has upon 
human growth and development, it would be interesting to expand TGF-β2 related 
studies to pastoral societies. These populations could provide further information about 
the cross-reactivity of various mammalian milks and breastmilk on human growth and 
development. These populations, however, often live in geographic areas which are 
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difficult to access, again emphasizing the need for more field-friendly methods not only 
for sample storage, but perhaps sample analysis in the field.  
The concentration of TGF-β2 in human breastmilk is population dependent, 
highly reactionary to the maternal ecological and immunological environments (Miller 
2018). This adaptive dispensing of TGF-β2 walks a fine line – too little and the infant 
can suffer from disease and inflammation, too much and the infant immune system 
becomes overactive (Agarwal et al. 2011). Given the integral role TGF-β2 plays in 
immune function and maintenance, especially in regards to inflammation, researchers 
are investigating the therapeutic possibilities of TGF-β2 in ameliorating chronic 
inflammatory diseases as well as autoimmune diseases (Jung et al. 1994; Rißmann et al. 
2008). While little research has been done on this front, preliminary findings are 
promising. Namachivayam et al. (2015) were able to successfully isolate the TGF-β2 in 
preterm human milk and enhance its bioactivity through a chondroitin sulfate 
treatment, the effects of which were found to protect against inflammatory bowel 
disease in infants.  
TGF-β2 from bovine milk has also been speculated to offer a therapeutic avenue 
for chronic inflammatory disease and autoimmune disease treatment and management 
(Donnet-Hughes et al. 2000; Russ et al. 2010). A diet rich in activate, bovine TGF-β2 has 
been shown to result in remission of Cohn’s disease in adolescent patients (Donnet-
Hughes et al. 2000). Experiments to create supplements from bovine whey with high 
64 
 
concentrations of TGF-β2 for potential therapeutic use are also being explored (Forster 
et al. 2014). While these experiments offer very exciting insight into the potential 
biochemical application of TGF-β2 in health, there are important ethical considerations 
which must be taken into account.  
Promoting the consumption of cow’s milk to improve growth and immune 
function is a thorny proposition, fraught with controversy. The vast majority of adult 
humans are lactose intolerant, yet milk marketing in the United States represents 
drinking cow’s milk as an indisputable staple of the daily diet (Wiley 2014; 2007). While 
drinking cow’s milk at during early stages of life has been found to improve height and 
gut immune function, but these protective effects have not been reported to carry over 
into adulthood (Wiley 2009, 2005). These findings illustrate a potential therapeutic use 
for bovine TGF-β2 for those who suffer from chronic inflammation, but by no means do 
they insinuate that bovine milk consumption is a mandatory element for human 
development (Wiley 2007). 
Given that humans do consume milks other than their own, however, future 
research regarding TGF-β2 should consider a multi-milk approach. TGF-β2 in milk has 
the potential to offer a great deal of insight into the evolution and development of 
human growth and immunity. Learning how we consume and utilized this cytokine is 
pivotal to furthering our understanding of human health, especially in regards to 
chronic inflammatory and autoimmune diseases. By assessing TGF-β2 in milk through 
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biocultural and ecological immunity perspectives, we can develop an evolutionary 
perspective on developmental human immunity and how it effects health across the life 
course.  
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Appendix B: Laboratory Protocol 
 
Human TGF-B2 R&D DuoSet ELISA for dried milk samples for the Health & Human 
Biology Laboratory 
 
Materials:  
R&D DuoSet ELISA for Human TGF-B2 (Catalog #DY302). Store at 2-8°C 
a.) Human TGF-B2 Capture Antibody (840405). 
b.) Human TGF-B2 Detection Antibody (804406).  
c.) Human TGF-B2 Standard (840407). 
d.) Streptavidin-HRP (890803). 
1. 96-well microplates. Fisherbrand 96-well flat-bottomed MaxiSorp plates. 
(Catalog #12-565-136) 
2. Adhesive plate sealers or parafilm 
3. Wash buffer: phosphate-buffered saline (7.2 pH) with 0.05% Tween-20 Store at 2-
8°C 
4. Reagent buffer: R&D Reagent Diluent Concentrate 2 (Catalog #DY995) Store at 2-
8°C 
5. Sample Activation Kit (R&D Systems, Catalog #DY010) 
6. Substrate: 1-Step TMB Ultra (Pierce) Store at 2-8°C 
7. Controls: R&D Immunoassay Control Group 3 (Catalog #QC20) Store at 2-8°C 
Preparation of Reagents 
I. Phosphate-buffered saline (PBS) 
 NaH2PO4•H2O   0.345 g 
 Na2HPO4•H2O   2.680 g 
NaCl    8.474 g  
Dissolve in ~900 mL deionized H2O 
Check pH 7.2 (± 0.3) and adjust to 1 L 
II. Wash buffer: phosphate-buffered saline with 0.05% Tween-20 
 NaH2PO4•H2O   0.345 g 
 Na2HPO4•H2O   2.680 g 
NaCl    8.474 g  
Tween-20   0.500 mL 
Dissolve in ~900 mL deionized H2O 
Check pH 7.2 (± 0.3) and adjust to 1 L 
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III. Dilution buffer: R&D Reagent Diluent Concentrate, diluted for a final concentration 
of 1% bovine serum albumin (BSA)  
Dissolve 10 mL concentrate in 90 mL deionized H2O 
IV. Controls: Follow instructions in package for reconstituting controls. Pipette controls 
directly into wells with no dilution. Store at 2-8°C. 
 
Assay Procedure 
 
Day One 
 
1. Mix 35 µL capture antibody in 6265 µL PBS. Make sure you use plain PBS only! 
Pipette 50 µL capture antibody solution into each well of a 96-well plate, making 
sure the bottom of each well is fully covered. Pipette tips may be rested on the 
bottom of the well to ensure proper coverage. Tap sides of plate if necessary to 
spread solution. Cover and incubate at room temperature overnight. 
Day Two 
2. Bring all reagents to room temperature before use. This step is critical on both days 
for all reagents, as this assay is susceptible to edge effects! Wash plate 3 times with 
Wash Buffer (PBS+Tween-20) in plate washer (use at least 300 µL in each well). Tap 
firmly on paper towel to dry. 
 
3. Add 300 µL Reagent Diluent to each well and incubate for at least one hour. This 
blocks the plate. 
 
4. Reconstitute dried samples with Reagent Diluent at a 1:1 ratio for 20-30 minutes on 
plate shaker.  
 
5. Prepare samples as follows (for every 25 µL): 
• Add 5 µL HCl activator to 25 µL sample and mix well. Incubate 10 
minutes. 
• Add 5 µL NaOH deactivator and mix well. 
• Add 100 µL of Reagent Diluent to samples and mix. Use within 2 hours of 
activation. 
 
6. Prepare standards as follows: 
78 
 
• Mix 20 µL standard into 530 µL Reagent Diluent (2000 pg/mL standard) 
• Perform a two-fold serial dilution of standards by pipetting 250 µL of 
higher standard into 250 µL Reagent Diluent six times. Final 
concentrations will be 2000, 1000, 500, 250, 125, 62.5, 31.25 pg/mL. One 
standard should be Reagent Diluent only, with a concentration of 0. You 
will have a total of 8 standard values 
 
7. Pipette 50 µL of standards, controls and samples into each well in duplicate. Cover 
and incubate for 2 hours at room temperature. Wash 3x in plate washer as above. 
 
8. Prepare detection antibody by pipetting 35 µL of Detection Antibody into 6265 µL of 
Reagent Diluent. Mix well. Pipette 50 µL of detection antibody solution into each 
well. Cover and incubate for 2 hours at room temperature. Wash 3x in plate washer 
as above. 
 
9. Prepare Streptavidin-HRP solution by pipetting 20 µL of Strep-HRP concentrate into 
7980 µL of Reagent Diluent. Check dilution instructions on bottle to confirm proper 
dilution. Mix well. Pipette 50 µL of strep-HRP solution into each well. Incubate for 
20 minutes at room temperature; keep shielded from light. Wash 3x in plate washer 
as above.  
 
10. Pipette 50 µL 1-step TMB Ultra into each well using a multichannel pipette. Incubate 
for 20 minutes at room temperature; keep shielded from light. 
 
11. Pipette 25 µL 2 N H2SO4 into each well to stop the reaction. Read immediately in 
Epoch reader, using Gen 5 software. The protocol for this assay is called “TGFB2.” 
Multiply samples by 5.4 to account for sample dilution. Re-assay samples that are 
out of range of standard curve or duplicates with a %CV > 10%. 
 
 
